Loading clinical trials...
Loading clinical trials...
A Randomised, Placebo-controlled, Double-blind, Two Period Crossover Study to Characterise the Exhaled Nitric Oxide Time Profile as a Biomarker of Airway Inflammation in Adult Asthma Patients Following Repeat Administration of Inhaled Fluticasone Furoate (FF)/ Vilanterol (VI) 100/25 mcg.
Conditions
Interventions
Fluticasone furoate (FF) (100 mcg)
Vilanterol (VI) (25 mcg)
+1 more
Locations
1
New Zealand
GSK Investigational Site
Newtown, Wellington, New Zealand
Start Date
April 29, 2016
Primary Completion Date
February 21, 2017
Completion Date
February 21, 2017
Last Updated
August 28, 2018
NCT07486401
NCT02327897
NCT07219173
NCT04706988
NCT04639791
NCT06471257
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions